Mainz Biomed BV
NASDAQ: MYNZ · HEALTHCARE · DIAGNOSTICS & RESEARCH
Updated 2026-05-01
Mainz Biomed BV (MYNZ) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for MYNZ.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
MYNZ historical valuation range
Where current P/E sits in MYNZ's own 5Y range.
MYNZ intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
MYNZ valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 16.01x
Is MYNZ overvalued in 2026?
Mainz Biomed BV (MYNZ) currently trades at $0.41 per share with a market capitalization of $7,902,800.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 18/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
MYNZ currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 16.0x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates MYNZ's intrinsic value at $0.52 per share, against the current market price of $0.41. This implies a premium to fair value of -62.85%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
The Piotroski F-Score of 6/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: MYNZ appears richly valued on our framework, with a Smart Value Score of 18/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is MYNZ overvalued in 2026?
Based on a Smart Value Score of 18/100, MYNZ appears overvalued. Current price exceeds what fundamentals currently justify.
What is MYNZ's fair value?
Our DCF model estimates MYNZ's intrinsic value at $0.52 per share, versus the current price of $0.41. This produces a margin of safety of -62.85%.
What P/E ratio does MYNZ trade at?
MYNZ does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is MYNZ a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 18/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does MYNZ's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on MYNZ.
What is MYNZ's Smart Value Score?
MYNZ's Smart Value Score is 18/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.